PLOD2 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Images
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Alternative names
2-oxoglutarate 5-dioxygenase 2, LH2, Lysine hydroxylase 2, Lysyl hydroxylase 2, OTTHUMP00000215204, OTTHUMP00000215205, OTTHUMP00000215206, PLOD2_HUMAN, Procollagen lysine 2 oxoglutarate 5 dioxygenase 2, Procollagen lysine, 2 oxoglutarate 5 dioxygenase (lysine hydroxylase) 2, Procollagen-lysine, TLH, Telopeptide lysyl hydroxylase
What's included?
Recommended products
PLOD2 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
- Concentration
Properties
- Gene name
- PLOD2
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Sanger Sequencing - Human PLOD2 (PLOD2/LH2) knockout HEK-293T cell lysate (ab258591)
Homozygous: 1 bp insertion in exon4
Western blot - Human PLOD2 (PLOD2/LH2) knockout HEK-293T cell lysate (ab258591)
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Lysates at 20 µg per lane.
The samples were run on a Bis-Tris gel under reducing conditions. Western blot: Anti-PLOD2/LH2 antibody (Anti-PLOD2/LH2 antibody [EPR25160-20] ab313765) staining at 1/1000 dilution, shown in green;Mouse anti-GAPDH antibody 6C5 (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red.
In Western blot, Anti-PLOD2/LH2 antibody [EPR25160-20] ab313765 was shown to bind specifically to PLOD2/LH2
Target of interest was observed at 95 kDa in wild-type Hela cell lysates (lane 1) with no signal observed at this size in PLOD2 knockout cell line Human PLOD2 (PLOD2/LH2) knockout HEK-293T cell line ab266279 (knockout cell lysate ab258591) (lane 2). To generate this image, samples were first run on an SDS-PAGE gel then transferred onto an immobilon-FL PVDF membrane. Membranes were blocked in a fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4 °C. Blots were washed in TBS-T, incubated with secondary antibodies Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution for 1 h at room temperature, washed again then imaged.All lanes: Western blot - Anti-PLOD2/LH2 antibody [EPR25160-20] (Anti-PLOD2/LH2 antibody [EPR25160-20] ab313765) at 1/1000 dilution
Lane 1: Wild-type HEK293T (human embryonic kidney epithelial cell) whole cell lysate at 20 µg
Lane 2: Western blot - Human PLOD2 (PLOD2/LH2) knockout HEK-293T cell lysate (ab258591) at 20 µg
Lane 3: HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 4: A431 (human epidermoid carcinoma epithelial cell) whole cell lysate at 20 µg
SecondaryAll lanes: Goat Anti-Rabbit IgG H&L (800CW) and Goat Anti-Mouse IgG H&L (680RD) at 1/20000 dilution
Performed under reducing conditions.
Observed band size: 95 kDa
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com